Add-on Eye Movement Desensitization and Reprocessing (EMDR) Therapy for Adults with Post-traumatic Stress Disorder Who Failed to Respond to Initial Antidepressant Pharmacotherapy.
Hwallip BaeYongrae ChoYubin ChoDongjoo KimSeok Hyeon KimPublished in: Journal of Korean medical science (2018)
This study examined the add-on efficacy of eye movement desensitization and reprocessing (EMDR) therapy among adult civilians with post-traumatic stress disorder (PTSD) who continued to be symptomatic after more than 12 weeks of initial antidepressant treatment. Scores for the Clinician Administered PTSD Scale (CAPS) were rated pre- and post-EMDR and at a 6-month follow-up. After an average of six sessions of EMDR treatment, seven of 14 patients (50%) showed more than a 30% decrease in CAPS score and eight (57%) no longer met the criteria for PTSD. Our results indicate that EMDR could be successfully added after failure of initial pharmacotherapy for PTSD.
Keyphrases
- social support
- posttraumatic stress disorder
- end stage renal disease
- major depressive disorder
- ejection fraction
- chronic kidney disease
- depressive symptoms
- smoking cessation
- stem cells
- peritoneal dialysis
- tyrosine kinase
- replacement therapy
- young adults
- combination therapy
- bipolar disorder
- cell therapy
- bone marrow
- patient reported